Table 2. Clinicopathological characteristics in 117 lung cancer patients with platinum- based chemotherapy.
RASBs renin-angiotensin system blockers; ACEIs angiotensin-converting enzyme inhibitors; ARBs angiotensin-2 receptor 1 blockers; SD standard deviation; NSCLC non-small cell lung cancer; SCLC small cell lung cancer.
| Characteristic | Non- RASBs, n = 79 | RASBs | |||||
|---|---|---|---|---|---|---|---|
| Total, n = 38 | P-valuea | ACEIs, n = 20 | P-valuea | ARBs, n = 18 | P-valuea | ||
| Gender, n (%) | |||||||
| Male | 62 (78.5) | 26 (68.4) | 0.238 | 13 (65.0) | 0.335 | 13 (72.2) | 0.795 |
| Female | 17 (21.5) | 12 (31.6) | 7 (35.0) | 5 (27.8) | |||
| Age, years, n (%) | |||||||
| Mean ± SD | 62.96 ± 8.02 | 61.08 ± 7.89 | 0.995 | 61.35 ± 6.60 | 0.439 | 60.78 ± 9.31 | 0.425 |
| ≤60 | 27 (34.2) | 17 (44.7) | 0.269 | 10 (50.0) | 0.191 | 7 (38.9) | 0.705 |
| >60 | 52 (65.8) | 21 (55.3) | 10 (50.0) | 11 (61.1) | |||
| Smoking status, n (%) | |||||||
| Never | 26 (32.9) | 18 (47.4) | 0.131 | 9 (45.0) | 0.312 | 9 (50.0) | 0.173 |
| Ever | 53 (67.1) | 20 (52.6) | 11 (55.0) | 9 (50.0) | |||
| Histology, n (%) | |||||||
| NSCLC | 60 (75.9) | 31 (81.6) | 0.567 | 16 (80.0) | 0.766 | 15 (83.3) | 0.543 |
| Adenocarcinoma | 43 (54.4) | 19 (50.0) | 11 (55.0) | 8 (44.4) | |||
| Squamous | 17 (21.5) | 12 (31.6) | 5 (25.0) | 7 (38.9) | |||
| SCLC | 18 (22.8) | 7 (18.4) | 4 (20.0) | 3 (16.7) | |||
| Others | 1 (1.3) | 0 (0) | 0 (0) | 0 (0) | |||
| Tumor size, n (%) | |||||||
| Mean ± SD | 45.95 ± 19.39 | 49.55 ± 21.27 | 0.372 | 49.61 ± 17.99 | 0.797 | 49.47 ± 25.33 | 0.094 |
| ≤3 cm | 18 (22.8) | 6 (15.8) | 0.482 | 2 (10.0) | 0.196 | 4 (22.2) | 0.849 |
| >3 cm | 56 (70.9) | 27 (71.0) | 16 (80.0) | 11 (61.1) | |||
| Unknown | 5 (6.3) | 5 (13.2) | 2 (10.0) | 3 (16.7) | |||
| Pathological grade, n (%) | |||||||
| Well | 2 (2.5) | 3 (7.9) | 0.305 | 3 (15.0) | 0.107 | 0 (0) | 0.690 |
| Moderately | 14 (17.7) | 7 (18.4) | 4 (20.0) | 3 (16.7) | |||
| Poorly | 29 (36.7) | 10 (26.3) | 5 (25.0) | 5 (27.8) | |||
| Unknown | 34 (43.1) | 18 (47.4) | 8 (40.0) | 10 (55.5) | |||
Notes.
a
Each group was separately compared with the Non-RASBs group.